ArticleTransactions on machine learning research2026
Tumor-anchored deep feature random forests for out-of-distribution detection in lung cancer segmentation.
Article in Transactions on machine learning research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Accurate segmentation of lung tumors from 3D computed tomography (CT) scans is essential for automated treatment planning and response assessment. Despite self-supervised pre-training on numerous datasets, state-of-the-art transformer backbones remain susceptible to out-of-distribution (OOD) inputs, often producing confidently incorrect segmentations with potential risk in clinical deployment. Hence, we introduce RF-Deep, a lightweight post-hoc random forests-based framework that uses deep features trained with limited outlier exposure, requiring as few as 40 labeled scans (20 in-distribution and 20 OOD), to improve scan-level OOD detection. RF-Deep repurposes the hierarchical features from the pretrained-then-finetuned segmentation backbones, aggregating features from multiple regions-of-interest anchored to predicted tumor regions to capture OOD likelihood. We evaluated RF-Deep on 2,232 CT volumes spanning near-OOD (pulmonary embolism, COVID-19 negative) and far-OOD (kidney cancer, healthy pancreas) datasets. RF-Deep achieved AUROC > 93 on the challenging near-OOD datasets, where it outperformed the next best method by 4-7 percentage points, and produced near-perfect detection (AUROC > 99) on far-OOD datasets. The approach also showed transferability to two blinded validation datasets under the ensemble configuration (COVID-19 positive and breast cancer; AUROC > 94). RF-Deep maintained consistent performance across backbones of different depths and pretraining strategies, demonstrating applicability of post-hoc detectors as a safety filter for clinical deployment of tumor segmentation pipelines.
Identifiers
42370064PMC13298336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.